Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial
Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Franck Morschhauser(Hôpital Claude Huriez), Ellen Ingalla, Martine E.D. Chamuleau(Hovon), Steven Le Gouill(Inserm), Divya Samineni, Laurie H. Sehn(BC Cancer Agency), Arijit Sinha(Roche (United Kingdom)), Guillaume Cartron(Hôpital Saint Eloi), Constantine S. Tam(The Alfred Hospital), Edith Szafer‐Glusman, Kylie D. Mason(The Royal Melbourne Hospital), Deepak Sampath, Carla Casulo(University of Rochester Medical Center), Martin Kornacker(Roche (Switzerland)), Christian Klein(Roche (Switzerland)), Adam M. Petrich(AbbVie (United States)), Pieternella J. Lugtenburg(Erasmus MC Cancer Institute), Gilles Salles(Memorial Sloan Kettering Cancer Center), André Goy(Hackensack University Medical Center), Hervé Tilly(Centre Virchow-Villermé), Mehrdad Mobasher(University Hospital Cologne), Sylvia Herter(Roche (Switzerland))
Cited by 136
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k